calcium;4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoic acid;4-[[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxidobutylidene]amino]butanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: calcium;4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoic acid;4-[[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxidobutylidene]amino]butanoate
• 化学式: C20H36CaN2O10
• 分子量: 504.6
• InChiKey: OVXZVDMCQPLHIY-QXGOIDDHSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -4.36
• 重原子数：
  33
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  219
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  calcium;4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoic acid;4-[[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxidobutylidene]amino]butanoate 生成 4-[[(2R)-2,4-二羟基-3,3-二甲基-1-氧代丁基]氨基]-丁酸
  参考文献：
  名称：

  YONEDA, NAOTO;HAYASHI, KIMIAKI;SUGAWARA, YOICHI;HARIGAYA, SHOICHI

  摘要：

  DOI：

文献信息

• [EN] CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATEURS DE CALPAÏNE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BLADE THERAPEUTICS INC

  公开号：WO2019190885A1

  公开（公告）日：2019-10-03

  Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

  小分子钙蛋白酶调节剂化合物，包括其药用可接受的盐，可以包含在药物组合物中。这些化合物可以通过与主体内的CAPN1、CAPN2和/或CAPN9酶接触来抑制钙蛋白酶，或与钙蛋白酶抑制剂竞争性结合。这些化合物和组合物也可以被用于治疗纤维化疾病或纤维化疾病的继发疾病状态或病情。
• [EN] SELF-ASSEMBLED MICROCAPSULES WITH STIMULI-RESPONSIVE ORGANIC LIGANDS<br/>[FR] MICROCAPSULES AUTO-ASSEMBLÉES AVEC DES LIGANDS ORGANIQUES SENSIBLES AUX STIMULI
  申请人：UNIV CALIFORNIA

  公开号：WO2020106875A1

  公开（公告）日：2020-05-28

  Self-assembled organic ligand functionalized microcapsules encapsulating one or more substrates, which release the substrates upon activation with a power source, are provided. Compositions that include these microcapsules, as well as methods of making the microcapsules and releasing the encapsulated substrates are also provided. The structures, compositions and methods find use in a variety of applications, such as drug and cell encapsulation technologies, for direct delivery, control, and activation of medicines and therapies to specific tissues in a living host.

  提供自组装的有机配体功能化微囊，封装一个或多个底物，这些底物在用电源激活后释放。包括这些微囊的组合物，以及制造微囊和释放封装底物的方法也提供。这些结构、组合物和方法在多种应用中有用武之地，例如药物和细胞封装技术，用于直接输送、控制和激活活体宿主中特定组织的药物和疗法。
• [EN] PHOSPHOPANTETHEINE COMPOUNDS ALONE OR IN COMBINATION WITH HMG-COA REDUCTASE INHIBITORS FOR LOWERING SERUM CHOLESTEROL AND SERUM TRIGLICERIDES<br/>[FR] COMPOSÉS DE PHOSPHOPANTÉTHÉINE SEULS OU EN COMBINAISON AVEC DES INHIBITEURS DE HMG-COA RÉDUCTASE PERMETTANT D'ABAISSER LE CHOLESTÉROL SÉRIQUE ET LES TRIGLYCÉRIDES SÉRIQUES
  申请人：ACIES BIO D O O

  公开号：WO2016102680A1

  公开（公告）日：2016-06-30

  The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

  这项发明涉及单独使用及与3-羟基-3-甲基戊二酸辅酶A还原酶抑制剂联合使用磷脂酰泛醌化合物。优选的医疗用途涉及治疗或预防血脂异常。
• [EN] COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INDUCTION D'UNE TOLÉRANCE IMMUNITAIRE
  申请人：UNIV CHICAGO

  公开号：WO2018232176A1

  公开（公告）日：2018-12-20

  Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.

  本公开提供的一些实施例涉及承载期望产生耐受性的抗原的组成物，该抗原通过与靶向部分耦合、结合或以其他方式连接，该靶向部分配置为将组成物导向受试者的肝脏。在一些实施例中，通过聚合物连接剂将抗原与靶向部分连接。在一些实施例中，聚合物连接剂配置为在体内释放抗原。还提供了使用这些组成物来减少和/或预防对感兴趣抗原的未期望免疫反应的方法。
• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。